CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Pasithea Therapeutics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Pasithea Therapeutics Corp
1111 Lincoln Road
Phone: (786) 977-3380p:786 977-3380 MIAMI BEACH, FL  33139  United States Ticker: KTTAKTTA
Business Summary
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
8049 Offices and clinics of health practitioners, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman, Co-Founder LawrenceSteinman 75 8/1/2020 8/1/2020
Chief Executive Officer, Director Tiago R.Marques 46 8/1/2020 8/1/2020
Chief Financial Officer Daniel H.Schneiderman 45 10/11/2022 10/11/2022
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Alpha-5 integrin, LLC 200 Garrett St Charlottesvilee VA United States

Business Names
Business Name
AlloMek Therapeutics, LLC
Alpha 5 Integrin, LLC
Alpha-5 integrin, LLC
4 additional Business Names available in full report.

General Information
Number of Employees: 8 (As of 12/31/2023)
Outstanding Shares: 1,042,415 (As of 3/23/2024)
Shareholders: 40
Stock Exchange: NASD
Federal Tax Id: 851591963


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024